ImageneBio financials
$4.58−1.29%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $800.0K |
| Gross profit | $800.0K |
| Gross margin | 100.0% |
| Operating income | -$48.5M |
| Net income | -$52.4M |
| Net margin | −6549.4% |
| Diluted EPS | $-10.76 |
| EBITDA | -$48.1M |
| Operating cash flow | -$47.8M |
| Free cash flow | -$47.8M |
| Diluted shares | 4.9M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $94.5M |
| Short-term investments | $40.8M |
| Total debt | $0.00 |
| Total assets | $153.0M |
| Total liabilities | $19.8M |
| Shareholders' equity | $133.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology